Interleukin inhibitors

What are Interleukin inhibitors?

Interleukin inhibitors are immunosuppressive agents which inhibit the action of interleukins. Interleukins are a group of cytokines which are synthesized by lymphocytes, monocytes, macrophages, and certain other cells. They function especially in regulation of the immune system.

Interleukin Inhibitors
These include anakinra (Kineret), canakinumab (Ilaris), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tocilizumab (Actemra) and ustekinumab (Stelara).

IL‐5 signalling is therefore an attractive target in asthma, and has yielded three monoclonal antibodies: mepolizumab (trade name Nucala; GlaxoSmithKline), reslizumab (trade names Cinqair or Cinqaero; Teva) and benralizumab (MedImmune/AstraZeneca).

Multiple pharmacologic inhibitors (sometimes termed blockers) of IL-6 are commercially available for clinical use, including monoclonal antibodies directed against the IL-6 receptor (IL-6R; eg, tocilizumab, sarilumab, and satralizumab) as well as monoclonal antibodies specific for IL-6 (eg, siltuximab and olokizumab).

IL-17 Inhibitors and Their Role in Inflammatory Bowel Disease. The best-known anti-IL-17 monoclonal antibodies are Secukinumab (SEC), Ixekizumab (IXE), and brodalumab (BROD), which are widely used in the treatment of IBD for psoriasis and ankylosing spondylitis.